Safety study of ABS-1230 for children with KCNT1 epilepsy
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a new drug called ABS-1230 in children and young adults with KCNT1-related epilepsy, a rare genetic form of epilepsy. The study will check if the drug is safe and if it helps reduce seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 month and 21 years old
- You have been diagnosed with KCNT1-related epilepsy (confirmed by a doctor)
- You have at least 4 countable motor seizures (seizures with movement) per week on average
- You are taking 6 or fewer anti-seizure medications, and can keep the same doses steady during the trial
- You are not currently taking phenytoin, carbamazepine, stiripentol, or quinidine (specific seizure or heart medications)
- You do not have other serious medical conditions that would make it unsafe for you to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called ABS-1230 in healthy people to see how safe it is and how the body processes it. You would take either the drug or a placebo (no active ingredient) and be monitored closely.
This trial looks at how safe brivaracetam is and how well it can be used in children and teens with certain types of epilepsy that are not well controlled. It may help families who are dealing with frequent focal seizures despite taking seizure medicines.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This study tests a drug called phenylbutyrate for people with seizures caused by SLC6A1 gene changes. The drug may help reduce seizure frequency. The trial is fully remote, so you can join from anywhere in the U.S. without going to a clinic.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
Hear when a new KCNT1-Related Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.